Phase 3 Peripheral Artery Disease Clinical Trials
4 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–4 of 4 trials
Recruiting
Phase 3
Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
Peripheral Artery Disease (PAD)
Regeneron Pharmaceuticals7,050 enrolled4 locationsNCT07318610
Recruiting
Phase 3
The COCOA-PAD II Trial
Peripheral Artery Disease
Northwestern University190 enrolled3 locationsNCT04794530
Recruiting
Phase 3
Improving Mobility After Revascularization in Peripheral Artery Disease
intermittent claudicationMobility LimitationPeripheral Artery Disease+2 more
Northwestern University386 enrolled7 locationsNCT06686121
Recruiting
Phase 3
Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee
Peripheral Artery DiseaseCritical Limb Ischemia
Mercator MedSystems, Inc.250 enrolled2 locationsNCT04433572